Summit rises after FDA accepts marketing application for lung cancer drug

Summit Therapeutics

29/01/2026 13:07

** Shares of drug developer Summit Therapeutics SMMT.O rise 3.71% to $16.22 premarket

** Co says the U.S. Food and Drug Administration has accepted its application to market its experimental drug to treat lung cancer

** Reports mixed results from patient subgroups in a longer-term follow-up of its late-stage trial in September

** The therapy is an antibody designed to block a protein called PD-1, which helps the body's immune system fend off cancer; Keytruda also targets the same protein

** The health regulator has assigned a new Prescription Drug User Fee Act (PDUFA) target action date for November 14, 2026 - SMMT

** Stock fell ~2% in 2025

(Reporting by Gnaneshwar Rajan in Bengaluru)

((Gnaneshwar.Rajan@thomsonreuters.com;))